What to know about the temporary Medicare GLP-1 Bridge program

Key Points:

• Starting July 1, 2026, the Medicare GLP-1 Bridge program will allow eligible Medicare Part D beneficiaries to access certain GLP-1 weight management medications for a flat $50 monthly copay, running through December 31, 2027.
• The program targets beneficiaries without a medically coverable indication for GLP-1s under Part D, primarily focusing on weight management despite these drugs also treating diabetes and heart conditions.
• Eligibility requires enrollment in specified Medicare plans and meeting BMI and health condition criteria, with no extra paperwork for beneficiaries beyond obtaining a prescription and prior authorization from their provider.
• Regulatory concerns include potential risks of fraud and misuse due to program operation outside standard Medicare coverage and the rise of telehealth prescriptions, though CMS has implemented checks such as detailed prior authorization forms.
• CMS has not disclosed cost estimates or enrollment projections for the program, and the $50 copay does not count toward deductibles or out-of-pocket maximums, leaving some questions about the program’s financial impact unanswered.